We are live on ! Find out more
ADVM

Adverum Biotechnologies

Delisted

ADVM was delisted on the 8th of December, 2025.

55 hedge funds and large institutions have $45M invested in Adverum Biotechnologies in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more capital invested

Capital invested by funds: $33.1M → $45M (+$11.9M)

0.54% more ownership

Funds ownership: 5.75%6.29% (+0.54%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

7% less funds holding

Funds holding: 5955 (-4)

22% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 18

44% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 9

Holders
55
Holders Change
-4
Holders Change %
-6.78%
% of All Funds
0.88%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
5
Increased
14
Reduced
18
Closed
9
Calls
$58K
Puts
Net Calls
+$58K
Net Calls Change
-$701K

ADVM Hedge Fund Activity: Q1 2023 in Review

55 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q1 2023, worth a combined $45M — up 36% from $33.1M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of ADVM and 5 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 14 added.

The largest buyer was Commodore Capital, opening a new position worth an estimated $3.54M. The largest seller was Sonic GP LLC, cutting an estimated $1.8M.

  • 55 institutional investors held Adverum Biotechnologies (ADVM) as of Q1 2023, down from 59 in Q4 2022.
  • Funds reported $45M of Adverum Biotechnologies stock for Q1 2023, up 36% quarter-over-quarter.
  • 5 funds opened new Adverum Biotechnologies positions in Q1 2023 and 9 closed out, a net change of -4 holders.
  • The largest Adverum Biotechnologies buyer in Q1 2023 was Commodore Capital, an estimated $3.54M added.
  • The largest Adverum Biotechnologies seller in Q1 2023 was Sonic GP LLC, an estimated $1.8M sold.

Based on aggregated 13F filings for Q1 2023.